Quality of life during first-line palliative chemotherapy for recurrent and metastatic head and neck cancer with weekly cisplatin and docetaxel

Journal of Cancer Research and Clinical Oncology

Volumn 135, Issue 7, 2009, Pages 901-908

  Guntinas Lichius, Orlando ^a   Rühlow, Sarah ^b   Veelken, Florian ^b   Klussmann, Jens Peter ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

Cisplatin; Docetaxel; Metastatic head and neck cancer; Palliation; Palliative chemotherapy; Quality of life

Indexed keywords

CISPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; TAXOID;

ADULT; AGED; ARTICLE; BLEEDING; BONE MARROW SUPPRESSION; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; HEAD AND NECK CANCER; HUMAN; HYPERSENSITIVITY REACTION; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SENSORY DYSFUNCTION; SIDE EFFECT; SKIN MANIFESTATION; SPEECH DISORDER; SWALLOWING; TREATMENT RESPONSE; ADJUVANT THERAPY; CARCINOMA; DRUG ADMINISTRATION; FEMALE; HEAD AND NECK TUMOR; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PSYCHOLOGICAL ASPECT; RECURRENT DISEASE; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM METASTASIS; PALLIATIVE CARE; QUALITY OF LIFE; RECURRENCE; SURVIVAL ANALYSIS; TAXOIDS;

EID: 66949123851     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-008-0525-9     Document Type: Article

References (21)

1. K Bjordal A De Graeff PM Fayers 2000 A 12 country field study of the EORTC QLQ-C30 (version 3.0) and the head and neck cancer specific module (EORTC QLQ-H&N35) in head and neck patients. EORTC Quality of Life Group Eur J Cancer 36 1796 1807 10.1016/S0959-8049(00)00186-6
2. K Bjordal M Ahlner-Elmqvist E Hammerlid 2001 A prospective study of quality of life in head and neck cancer patients. Part II. Longitudinal data Laryngoscope 111 1440 1452 10.1097/00005537-200108000-00022 (Pubitemid 32730193)
3. AL Carvalho IN Nishimoto JA Califano 2005 Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database Int J Cancer 114 806 816 10.1002/ijc.20740
4. D Curran N Aaronson B Standaert 2000 Summary measures and statistics in the analysis of quality of life data: an example from an EORTC-NCIC-SAKK locally advanced breast cancer study Eur J Cancer 36 834 844 10.1016/S0959-8049(00) 00056-3
5. D Curran J Giralt PM Harari 2007 Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab J Clin Oncol 25 2191 2197 10.1200/JCO.2006.08.8005
6. AI Dreyfuss JR Clark CM Norris 1996 Docetaxel: an active drug for squamous cell carcinoma of the head and neck J Clin Oncol 14 1672 1678 (Pubitemid 26134226)
7. B Ferrell J Paice M Koczywas 2008 New standards and implications for improving the quality of supportive oncology practice J Clin Oncol 26 3824 3831 10.1200/JCO.2007.15.7552
8. AA Forastiere B Metch DE Schuller 1992 Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: a Southwest Oncology Group study J Clin Oncol 10 1245 1251
9. A Forastiere W Koch A Trotti 2001 Head and neck cancer N Engl J Med 345 1890 1900 10.1056/NEJMra001375 (Pubitemid 33716564)
10. AA Forastiere T Leong E Rowinsky 2001 Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393 J Clin Oncol 19 1088 1095 (Pubitemid 32176285)
11. MK Gibson Y Li B Murphy 2005 Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group J Clin Oncol 23 3562 3567 10.1200/JCO.2005.01.057
12. BS Glisson BA Murphy G Frenette 2002 Phase II trial of docetaxel and cisplatin combination chemotherapy in patients with squamous cell carcinoma of the head and neck J Clin Oncol 20 1593 1599 10.1200/JCO.20.6.1593
13. NE Goldstein E Genden RS Morrison 2008 Palliative care for patients with head and neck cancer: "I would like a quick return to a normal lifestyle" JAMA 299 1818 1825 10.1001/jama.299.15.1818
14. O Guntinas-Lichius S Appenrodt F Veelken 2006 Phase II study of weekly docetaxel and cisplatin in patients with advanced recurrent and metastatic head and neck cancer Laryngoscope 116 613 618 10.1097/01.mlg.0000208366.34683.58
15. CA Karvonen-Gutierrez DL Ronis KE Fowler 2008 Quality of life scores predict survival among patients with head and neck cancer J Clin Oncol 26 2754 2760 10.1200/JCO.2007.12.9510
16. M Nordgren E Hammerlid K Bjordal 2008 Quality of life in oral carcinoma: a 5-year prospective study Head Neck 30 461 470 10.1002/hed.20735
17. L Peters K Sellick 2006 Quality of life of cancer patients receiving inpatient and home-based palliative care J Adv Nurs 53 524 533 10.1111/j.1365-2648.2006.03754.x
18. DB Shin SM Bang SH Park 2008 Correlation of quality of life with tumor response in patients receiving palliative chemotherapy for advanced gastrointestinal tumors Med Oncol 25 81 87 10.1007/s12032-007-0045-5
19. J Vermorken R Hitt L Geoffrois 2007 Cetuximab plus platinum-based therapy first-line in recurrent an/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): efficacy and safety results of a randomized phase III trial (EXTREME) Eur J Cancer Suppl 5 324
20. Vermorken J, Mesia R, Vega V et al (2007b) Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy-results of a randomized phase III (Extreme) study. In: 2007 annual ASCO meeting abtract No. 6091
21. W Yeo FK Mo J Koh 2006 Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma Ann Oncol 17 1083 1089 10.1093/annonc/mdl065